MARCO appears to be a potentially novel therapeutic marker that can be targeted to halt the progression of pulmonary fibrosis; it has been shown to promote macrophage polarization to a profibrotic M2 phenotype and precipitate an exaggerated fibrotic response to lung injury in a model of asbestosis (19). The gene discussed is MARCO; the disease is pulmonary fibrosis.